Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance
- 1 April 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (4-5) , 805-810
- https://doi.org/10.1016/0959-8049(92)90119-m
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patientsBritish Journal of Cancer, 1991
- Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoproteinBritish Journal of Cancer, 1990
- P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodiesBritish Journal of Cancer, 1990
- 21-day cycles of oral etoposide in heavily pretreated metastatic germ-cell cancerThe Lancet, 1990
- Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II studyCancer, 1990
- Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.Journal of Clinical Oncology, 1990
- Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects.Journal of Clinical Oncology, 1989
- Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein.Journal of Histochemistry & Cytochemistry, 1989
- Expression of Multidrug Resistance Gene in Human CancersJNCI Journal of the National Cancer Institute, 1989
- The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observationCancer Chemotherapy and Pharmacology, 1989